Want to see SYRE full AI Analyst Report?
Top Page
Spyre Therapeutics
(NASDAQ:SYRE)
Select Model
Select Model
Rating:62Neutral
Price Target:
$103.00
▲(41.08% Upside)
Action:Reiterated
Date:06/15/26
The score is driven by a very strong, low-leverage balance sheet and multiple positive Phase 2 trial updates, supported by favorable technical momentum. These positives are tempered by heavy ongoing losses and cash burn, and weak traditional valuation signals (negative P/E and no dividend).
Positive Factors
Balance Sheet Strength
Zero reported debt and a substantial equity base materially lower financial risk and provide durable funding flexibility to support multi-year R&D and trial programs. This reduces forced financing pressure and improves the company’s ability to execute clinical plans without immediate liquidity strain.
Negative Factors
High Cash Burn
Sustained negative operating and free cash flow at ~-$186M TTM reflects a high‑burn development model. Even with recent capital, continued program advancement and combination trials will require ongoing funding or significant reduction in burn, creating persistent financing and dilution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Zero reported debt and a substantial equity base materially lower financial risk and provide durable funding flexibility to support multi-year R&D and trial programs. This reduces forced financing pressure and improves the company’s ability to execute clinical plans without immediate liquidity strain.
Read all positive factors
Spyre Therapeutics (SYRE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.63B
Dividend YieldN/A
Average Volume (3M)1.13M
Price to Earnings (P/E)―
Beta (1Y)1.98
Revenue GrowthN/A
EPS Growth22.31%
CountryUS
Employees73
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.18
Shares Outstanding86,841,255
10 Day Avg. Volume1,376,756
30 Day Avg. Volume1,126,389
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)15.85
Price to Sales (P/S)0.00
P/FCF Ratio-66.98
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue57.32
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-26.65
Forecast
1Y Price Target
$101.50Price Target Upside39.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-2.92
Revenue Forecast (FY)N/A
Spyre Therapeutics Business Overview & Revenue Model
Company Description
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human mono...
How the Company Makes Money
Spyre Therapeutics does not primarily generate revenue from product sales because its programs are in clinical development and not commercialized. Its potential or typical sources of funding and revenue for a clinical-stage biotech include: (1) ra...
Spyre Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
84
Very Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 90.49M | 0.00 | 0.00 | 886.00K | 2.33M | 18.74M |
| Gross Profit | 0.00 | -171.65M | 0.00 | 886.00K | 2.33M | 18.74M |
| EBITDA | -194.65M | -209.56M | -207.97M | -127.60M | -81.99M | -64.08M |
| Net Income | -179.44M | -155.20M | -208.02M | -338.79M | -83.81M | -65.80M |
Balance Sheet | ||||||
| Total Assets | 763.95M | 777.78M | 608.48M | 341.86M | 71.14M | 109.93M |
| Cash, Cash Equivalents and Short-Term Investments | 741.47M | 756.53M | 603.09M | 339.28M | 55.71M | 93.13M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 4.63M | 5.06M |
| Total Liabilities | 93.14M | 62.55M | 90.68M | 157.84M | 20.84M | 25.98M |
| Stockholders Equity | 670.81M | 715.24M | 517.80M | 184.02M | 50.30M | 83.94M |
Cash Flow | ||||||
| Free Cash Flow | -185.80M | -169.25M | -157.41M | -99.91M | -80.18M | -54.29M |
| Operating Cash Flow | -185.80M | -169.25M | -157.41M | -99.91M | -80.14M | -53.72M |
| Investing Cash Flow | -86.83M | -143.47M | -353.29M | -108.39M | 57.01M | -22.62M |
| Financing Cash Flow | 321.33M | 309.02M | 410.91M | 361.08M | 42.68M | 1.39M |
Spyre Therapeutics Technical Analysis
Positive
73.01
Price Trends
75.95
Positive
59.68
Positive
42.77
Positive
Market Momentum
5.14
Negative
57.82
Neutral
37.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYRE, the sentiment is Positive. The current price of 73.01 is below the 20-day moving average (MA) of 81.35, below the 50-day MA of 75.95, and above the 200-day MA of 42.77, indicating a bullish trend. The MACD of 5.14 indicates Negative momentum. The RSI at 57.82 is Neutral, neither overbought nor oversold. The STOCH value of 37.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYRE.
Spyre Therapeutics Risk Analysis
Spyre Therapeutics disclosed 73 risk factors in its most recent earnings report. Spyre Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Spyre Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $7.63B | -40.32 | -31.25% | ― | ― | 22.31% | |
61 Neutral | $958.28M | ― | -153.61% | ― | 1.92% | -1130.30% | |
56 Neutral | $9.14B | -24.48 | -43.02% | ― | -100.00% | -24.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.14B | ― | -110.54% | ― | -86.41% | -45.44% | |
45 Neutral | $340.12M | ― | -43.82% | ― | ― | ― | |
43 Neutral | $686.03M | -5.62 | -57.09% | ― | ― | 19.41% |
* Healthcare Sector Average
SYRE
Spyre Therapeutics
87.89
72.92
487.11%
EYPT
EyePoint Pharmaceuticals
13.66
4.25
45.16%
PRAX
Praxis Precision Medicines
327.79
285.74
679.52%
SPRY
ARS Pharmaceuticals
8.54
-8.91
-51.06%
OCS
Oculis Holding
12.00
-7.41
-38.18%
UPB
Upstream Bio, Inc.
6.75
-4.23
-38.52%
Spyre Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Spyre Therapeutics Reports Strong Phase 2 SKYLINE Results
Positive
Jun 15, 2026
On June 15, 2026, Spyre Therapeutics reported positive 12-week induction topline results from Part A of its Phase 2 SKYLINE trial evaluating SPY002, an extended half-life anti-TL1A antibody, in moderately to severely active ulcerative colitis. In ...
Business Operations and Strategy
Spyre Expands SPY003 Rights Beyond Inflammatory Bowel Disease
Positive
Jun 1, 2026
On May 29, 2026, Spyre Therapeutics amended its SPY003 license agreement with Paragon Therapeutics, broadening its rights from solely inflammatory bowel disease to cover all therapeutic, prophylactic, palliative and diagnostic uses of SPY003. The ...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Spyre Therapeutics Shareholders Back Board, Governance Proposals
Positive
May 29, 2026
On May 27, 2026, Spyre Therapeutics held its Annual Meeting of Stockholders, at which investors elected three Class I directors — Mark McKenna, Cameron Turtle, and Laurie Stelzer — to serve terms extending to the 2029 annual meeting, r...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Spyre Therapeutics Raises Capital Through Completed Stock Offering
Positive
Apr 16, 2026
On April 14, 2026, Spyre Therapeutics, Inc. entered into an underwriting agreement with a syndicate of banks to offer 6,500,000 shares of common stock at $62.00 per share, along with a 30-day option for underwriters to purchase up to an additional...
Business Operations and StrategyPrivate Placements and Financing
Spyre Therapeutics Pauses At-The-Market Equity Offering Program
Negative
Apr 13, 2026
On April 13, 2026, Spyre Therapeutics suspended and terminated its at-the-market prospectus for the sale of common stock under a previously established Sales Agreement with TD Securities (USA) LLC. As a result, the company halted ATM equity sales ...
Business Operations and StrategyProduct-Related Announcements
Spyre Therapeutics Reports Positive Phase 2 SKYLINE Results
Positive
Apr 13, 2026
On April 13, 2026, Spyre Therapeutics reported positive 12-week induction topline results from Part A of its Phase 2 SKYLINE trial evaluating SPY001 in patients with moderate-to-severely active ulcerative colitis. The extended half-life anti-α...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.